N
21.60
-0.69 (-3.10%)
| 前收盘价格 | 22.29 |
| 收盘价格 | 22.03 |
| 成交量 | 114,403 |
| 平均成交量 (3个月) | 922,160 |
| 市值 | 2,312,344,832 |
| 价格/销量 (P/S) | 59.79 |
| 股市价格/股市净资产 (P/B) | 5.42 |
| 52周波幅 |
| 营业利益率 (TTM) | -85.89% |
| 稀释每股收益 (EPS TTM) | -2.21 |
| 季度收入增长率 (YOY) | 889.80% |
| 总债务/股东权益 (D/E MRQ) | 0.13% |
| 流动比率 (MRQ) | 10.61 |
| 营业现金流 (OCF TTM) | -154.16 M |
| 杠杆自由现金流 (LFCF TTM) | -108.73 M |
| 资产报酬率 (ROA TTM) | -29.27% |
| 股东权益报酬率 (ROE TTM) | -47.37% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | NewAmsterdam Pharma Company N.V | 看跌 | 看涨 |
AIStockmoo 评分
1.4
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.38 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 0.37% |
| 机构持股比例 | 87.04% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 30 Sep 2024 | 10,473,913 |
| Medicxi Ventures Management (Jersey) Ltd | 31 Dec 2024 | 2,869,565 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 48.00 (HC Wainwright & Co., 122.22%) | 购买 |
| 中 | 43.50 (101.39%) | |
| 低 | 36.00 (Needham, 66.67%) | 购买 |
| 平均值 | 42.75 (97.92%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 22.19 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| RBC Capital | 28 Jan 2025 | 40.00 (85.19%) | 购买 | 21.45 |
| 24 Jan 2025 | 40.00 (85.19%) | 购买 | 23.60 | |
| HC Wainwright & Co. | 14 Jan 2025 | 48.00 (122.22%) | 购买 | 23.67 |
| 30 Dec 2024 | 48.00 (122.22%) | 购买 | 25.60 | |
| Scotiabank | 11 Dec 2024 | 47.00 (117.59%) | 购买 | 25.57 |
| Needham | 05 Dec 2024 | 36.00 (66.67%) | 购买 | 18.07 |
| 21 Nov 2024 | 36.00 (66.67%) | 购买 | 20.12 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合